Cn /En

News Center

——

Company news

Industry news

Immunogenicity Detection Platform of InnoModels Biotechnology

Author:

InnoModels

Release time:

2024-08-28

In the field of biopharmaceuticals, the safety and efficacy of drugs are crucial aspects of the R&D process. Immunogenicity is one of the key indicators for assessing the potential risk of a drug, and the accuracy and reliability of its detection platform directly affects the process and results of new drug development. With its advanced immunogenicity testing platform, InnoModels Biotechnology (Beijing) Co., Ltd. provides strong technical support and guarantee for new drug R&D.
Platform background and strength:
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiaotong University. Relying on the stable domestic platforms of Humanized Immune System (HIS) and Human Tumor Xenograft (PDX), the company focuses on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services, and individualized medicine. These platforms and services provide new-generation experimental animal models close to the clinic for new drug discovery companies, translational medicine researchers and tumor patients, and help the research and development of oncology and tumor immunotherapy.
Advantages of Immunogenicity Detection Platform:
●Advanced technology and equipment
InnoModels' immunogenicity testing platform adopts advanced testing technology and equipment to ensure the accuracy and reliability of the test results. The platform is capable of comprehensively evaluating the immunogenicity of drugs, including cellular immunity, humoral immunity, and hypersensitivity reactions, which meets the testing needs at different stages of new drug development.
●Professional Team and Services
The platform has an experienced and skilled team, who not only have a strong background in immunology, but also have rich experience in drug discovery and development. This team is able to provide customers with professional immunogenicity research services, from experimental design, sample processing to data analysis, to ensure the accuracy and reliability of test results in all aspects.
●Comprehensive Evaluation Capabilities
InnoModels' immunogenicity testing platform is capable of providing comprehensive immunogenicity assessment services. By detecting the effect of a drug on the immune system and assessing the type and degree of immune response it may trigger, it provides a scientific basis for new drug development. This comprehensive assessment capability helps to reduce the risk of new drugs in clinical trials and improve the success rate of R&D.

Practical application case:
In the process of new drug development, a new drug project requires a comprehensive assessment of its immunogenicity before entering clinical trials. Through InnoModels' immunogenicity testing platform, the researchers conducted an in-depth study on the immunogenicity of the new drug. Experimental results showed that the drug would not trigger serious immune reactions during the clinical trial, providing a strong guarantee for the smooth progress of the clinical trial. This successful case fully proves the accuracy and reliability of InnoModels' immunogenicity testing platform.
Future Prospects:
With the continuous development of the biopharmaceutical field, the importance of immunogenicity testing in new drug discovery and development is becoming more and more prominent. InnoModels Biotechnology will continue to devote itself to technological innovation and upgrading, and constantly improve the performance and service level of its immunogenicity testing platform. In the future, the platform will be applied in more fields, providing more comprehensive and accurate evaluation services for new drug development, and contributing more to the health of mankind.
In conclusion, with its advanced technology, professional team and comprehensive evaluation capability, the immunogenicity testing platform of InnoModels Biotechnology plays a crucial role in new drug development. It is believed that in the future development, the platform will continue to lead the industry's progress and bring more innovations and breakthroughs to the biomedical field.

Introducing the InnoModels Biotechnology IC50 Cell Activity Assay Platform

Introduction to the SCID Mouse NK Efficacy Model of InnoModels Biotechnology

Introducing the InnoModels Biotechnology IC50 Cell Activity Assay Platform

Introduction to the SCID Mouse NK Efficacy Model of InnoModels Biotechnology

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License